☆ 4.7 Editorial Material

Which trial do we need? Comparison of 7 versus 14 days of antibiotic therapy for ventilator-associated pneumonia due to highly resistant gram-negative bacteria

CLINICAL MICROBIOLOGY AND INFECTION (2023)

Related references

Note: Only part of the references are listed.

Article Immunology

Less Is More? Antibiotic Treatment Duration in Pseudomonas aeruginosa Ventilator-Associated Pneumonia

Owen R. Albin et al.

Summary: Further study is needed to determine the optimal duration of antimicrobial treatment for ventilator-associated pneumonia caused by Pseudomonas aeruginosa. The recommended duration of antimicrobial treatment for this condition has evolved over the past few decades. This viewpoint provides a review of landmark trials and the evolution of expert consensus guidelines, highlighting the need for future research.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection

Editorial Material Immunology

Less Is More: A 7-Day Course of Antibiotics Is the Evidence-Based Treatment for Pseudomonas aeruginosa Ventilator-Associated Pneumonia

Mark L. Metersky et al.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection

Review Infectious Diseases

Use of biomarkers to individualize antimicrobial therapy duration: a narrative review

Jake Scott et al.

Summary: Reducing the overuse of antimicrobials is important. Biomarkers, such as procalcitonin and C-reactive protein, can be used to guide the duration of antimicrobial therapy. However, the reliability of hematological biomarkers is limited and further research is needed.

CLINICAL MICROBIOLOGY AND INFECTION (2023)

Add to Collection

Review Infectious Diseases

Shorter antibiotic courses in the immunocompromised: the impossible dream?

Hannah Imlay et al.

Summary: A growing number of studies have shown that shorter courses of antibiotics can achieve similar outcomes for bacterial infections. However, immunocompromised patients, who could benefit from shorter antibiotic courses, are often excluded from these studies.

CLINICAL MICROBIOLOGY AND INFECTION (2023)

Add to Collection

Review Medicine, General & Internal

Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials

Mohamed Aziz Daghmouri et al.

Summary: This meta-analysis examined the impact of short-course and long-course antibiotic therapy on the recurrence and relapse of ventilator-associated pneumonia (VAP). The results showed that short-course antibiotic therapy did not increase the risk of VAP recurrence and relapse, and also increased the number of antibiotic-free days.

ECLINICALMEDICINE (2023)

Add to Collection

Article Immunology

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections

Pranita D. Tamma et al.

Summary: The Infectious Diseases Society of America (IDSA) has provided updated guidance on the treatment of antimicrobial-resistant infections, focusing on treating AmpC-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. The guidance is based on clinical experience, expert opinion, and a review of available literature, as published data on optimal treatment options are limited. This document emphasizes treatment approaches for infections in the United States, considering differences in resistance epidemiology and the availability of specific anti-infectives internationally.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Infectious Diseases

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

Mical Paul et al.

Summary: These guidelines address the targeted antibiotic treatment of 3GCephRE and carbapenem-resistant Gram-negative bacteria, focusing on the effectiveness of individual antibiotics and on combination versus monotherapy. Most recommendations are based on low-certainty evidence.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Add to Collection

Article Immunology

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

Pranita D. Tamma et al.

Summary: This article provides updated guidance on the treatment of infections caused by ESBL-E, CRE, and DTR-P. aeruginosa. The guidance was developed by a panel of infectious diseases specialists and includes preferred and alternative treatment recommendations. The document emphasizes the importance of consulting with an infectious diseases specialist for the treatment of antimicrobial-resistant infections.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Critical Care Medicine

Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial

Adrien Bougle et al.

Summary: In the treatment of ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa (PA-VAP), there is no difference in the composite or separate outcomes between short- and long-duration antibiotic treatments.

INTENSIVE CARE MEDICINE (2022)

Add to Collection

Article Immunology

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Ivan Titov et al.

Summary: The study demonstrated that imipenem/cilastatin/relebactam and piperacillin/tazobactam had similar efficacy in treating hospital-acquired/ventilator-associated bacterial pneumonia. Imipenem/cilastatin/relebactam showed favorable safety profile in treating HABP/VABP patients.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Richard G. Wunderink et al.

Summary: Cefiderocol was found to be non-inferior to high-dose, extended-infusion meropenem in terms of all-cause mortality on day 14 in patients with Gram-negative nosocomial pneumonia, with similar tolerability. This suggests that cefiderocol is a potential option for the treatment of patients with nosocomial pneumonia, including those caused by multidrug-resistant Gram-negative bacteria.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial

Elodie von Dach et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Review Infectious Diseases

Relationship between Virulence and Resistance among Gram-Negative Bacteria

Virginio Cepas et al.

ANTIBIOTICS-BASEL (2020)

Add to Collection

Article Infectious Diseases

Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial

Marin H. Kollef et al.

LANCET INFECTIOUS DISEASES (2019)

Add to Collection

Article Respiratory System

International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia

Antoni Torres et al.

EUROPEAN RESPIRATORY JOURNAL (2017)

Add to Collection

Article Immunology

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

Andre C. Kalil et al.

CLINICAL INFECTIOUS DISEASES (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.